Address Depression in Patients With Metastatic Disease

• Read more about Address Depression in Patients With Metastatic Disease
• Add new comment

Patients who are diagnosed with cancer can experience depression, which is associated with poor health behavior and overall prognosis. A cross-sectional study sought to examine sociodemographic and clinical factors that might predict depression in patients with metastatic tumor. The researchers presented the study at the ASCO Annual Meeting.

Large Study Examines the Extent of Treatment-Related Adverse Events

• Read more about Large Study Examines the Extent of Treatment-Related Adverse Events
• Add new comment

Many studies focus on treatment-related toxicities, but limited data are available on the frequency, spectrum, and preventability of adverse events (AEs) across cancer care. The retrospective, cohort CHARM (Cancer Harm) study conducted manual reviews of medical records and reports from local databases to assess the nature and extent of AEs in patients with cancer. The researchers presented the study at the ASCO Annual Meeting.

Nurse-Led Patient Navigation Program Improves Cancer Survival

• Read more about Nurse-Led Patient Navigation Program Improves Cancer Survival
• 1 comment
• Add new comment

Patient navigation programs can help to improve outcomes and reduce disparities; however, little is known about their effects on clinical outcomes, such as survival. In a retrospective, cohort study, a nurse-led patient navigation program was initiated to assess 12-month survival outcomes. The researchers presented the study at the ASCO Annual Meeting.

Palbociclib Plus Fulvestrant Provides Benefit for Patients With HR+ Metastatic Breast Cancer

• Read more about Palbociclib Plus Fulvestrant Provides Benefit for Patients With HR+ Metastatic Breast Cancer
• Add new comment

Previous studies have demonstrated that ESR1 mu is a mechanism for acquired endocrine resistance in metastatic breast cancer (mBC). The randomized, double-blind, phase III PALOMA-3 study compared the use of palbociclib plus fulvestrant (P+F) versus fulvestrant plus placebo (F+Pla) in pre- and postmenopausal women with hormone receptor positive (HR+)/hormone estrogen receptor 2 negative mBC who have progressed on prior endocrine therapy. The researchers presented the study at the ASCO Annual Meeting.

Study Examines Treatment With Abemaciclib for HR+/HER2− Metastatic Breast Cancer

• Read more about Study Examines Treatment With Abemaciclib for HR+/HER2− Metastatic Breast Cancer
• Add new comment

Abemaciclib—an oral, selective inhibitor of CDK4 and CDK6—demonstrated single-agent activity in a phase I trial of patients with refractory hormone-receptor positive (HR+) metastatic breast cancer (mBC), with some tumor responses occurring after at least 8 months of treatment. The phase II, single-arm MONARCH1 study evaluated the safety and efficacy of abemaciclib monotherapy in women with HR+/hormone estrogen receptor 2 negative (HER2−) mBC who have progressed on or after endocrine therapy and chemotherapy. The researchers presented the study at the ASCO Annual Meeting.

ESR1 Mutation Reduces Overall Survival for HR+ Metastatic Breast Cancer

• Read more about ESR1 Mutation Reduces Overall Survival for HR+ Metastatic Breast Cancer
• Add new comment

Somatic and circulating activating ESR1 mutations have been shown to be related to aromatase inhibitor (AI) resistance in hormone receptor positive (HR+) metastatic breast cancer (mBC). In a monocentric, retrospective analysis, researchers sought to evaluate the predictive and prognostic values of circulating ESR1 mutation detection at time of disease progression in patients with mBC receiving AI treatment. The researchers presented the study at the ASCO Annual Meeting.

Encourage Breast Cancer Screening in Childhood Cancer Survivors

• Read more about Encourage Breast Cancer Screening in Childhood Cancer Survivors
• Add new comment

Female childhood cancer survivors who were treated with chest radiotherapy (RT) are advised to undergo annual mammography and breast magnetic resonance imaging (MRI) because of an increased risk for breast cancer, although methods to promote such screening are not well established. The randomized, controlled EMPOWER study investigated a screening intervention using mailing and brief motivational telephone interviews to promote breast cancer screening in women in the United States and Canada.

Year of Treatment May Predict Subsequent Neoplasm Risk Among Childhood Cancer Survivors

• Read more about Year of Treatment May Predict Subsequent Neoplasm Risk Among Childhood Cancer Survivors
• Add new comment

For childhood cancer survivors, limited data are available on whether historical changes in therapeutic exposure have altered subsequent neoplasm (SN) risk. Researchers used the Childhood Cancer Survivor Study to evaluate the occurrence of SNs in 23,603 survivors who were diagnosed earlier than 21 years of age and have reached five years of survival. The researchers presented the study at the ASCO Annual Meeting.

New Treatments and Insights in Multiple Myeloma

• Read more about New Treatments and Insights in Multiple Myeloma
• Add new comment

An interview with Beth Faiman, PhD, CNP, and Kimberly Noonan, NP

Test CPAF

• Read more about Test CPAF
• Add new comment

This is some test content.